Biocon Biologics receives EMA approval for cancer drug
The company received approval from the European Medicines Agency to manufacture biosimilar Bevacizumab at its new, multi-product monoclonal antibodies drug substance facility in Bengaluru.
usfda nod for cancer drug
June 2024
July 2023
Zydus Lifesciences gets USFDA nod for cancer drug; stock hits 52-week high
The share price of the drugmaker has risen 92% in the last one year from its 52-week low of ₹340.60 touched on July 27, 2022.
